New Triple-Threat attack on tough liver cancer
NCT ID NCT07327788
First seen Jan 11, 2026 · Last updated Apr 10, 2026 · Updated 11 times
Summary
This study is testing a three-part treatment for advanced liver cancer that has spread into a major vein in the liver. The treatment combines immunotherapy (QL1706), a drug that blocks tumor blood supply (bevacizumab), and chemotherapy delivered directly into the liver's artery. The main goal is to see how long patients live without their cancer getting worse and to check the safety of this combination approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATECELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanfang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.